The startup develops AI technology that detects mutations in plasma and identifies gene fusion events in solid tumor tissue, providing critical insights for cancer researchers and professionals. This capability enables tailored treatment plans and effective monitoring of cancer progression based on specific somatic mutations.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer researchers and professionals require accurate and efficient methods for detecting mutations in plasma and identifying gene fusion events in solid tumor tissue. Current methods may be time-consuming, expensive, or lack the sensitivity needed for early detection and personalized treatment strategies.
Solution
This startup offers an AI-powered platform designed to identify somatic mutations and gene fusion events in cancer samples. The technology analyzes plasma samples to detect circulating tumor DNA (ctDNA) and identifies gene fusions in solid tumor tissue, providing comprehensive genomic insights. By leveraging artificial intelligence, the platform aims to accelerate the identification of actionable mutations, enabling more tailored treatment plans and effective monitoring of cancer progression. The platform's analytical capabilities provide researchers and clinicians with the tools necessary to understand the unique genomic profiles of individual tumors.
Target Audience
The primary target audience includes cancer researchers, oncologists, pathologists, and pharmaceutical companies involved in cancer drug development.
Features
- AI-driven analysis of plasma samples for ctDNA mutation detection
- Identification of gene fusion events in solid tumor tissue
- Comprehensive genomic profiling for personalized treatment strategies
- Automated variant calling and annotation
- User-friendly interface for data visualization and interpretation